Shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) jumped over 20% today, after the drug maker announced the completion of the clinical phase of …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced the occurrence of the 384th death in the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) …
Maxim analyst Jason Kolbert is out with a bullish research report today on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) just one week after the …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are sinking 8% after the firm announced what Canaccord analyst Neil Maruoka deems “another disappointment for Macrilen,” …
On November 9th, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) posted third-quarter financial earnings and held a conference call.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are jumping nearly 5% after the biotech firm posted third-quarter results yesterday that with a pivotal clinical …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reported financial and operating results for the third quarter ended September 30, 2016.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that it intends to raise $7,560,000 in gross proceeds in a registered direct offering to a single healthcare …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced it has successfully completed patient recruitment for the confirmatory Phase 3 clinical trial of Macrilen™ (macimorelin) as a …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) and Specialised Therapeutics Asia (STA) announced the signing of an exclusive license agreement for the Company’s lead investigational anti-cancer …